<DOC>
	<DOC>NCT00463372</DOC>
	<brief_summary>To evaluate the safety and tolerability of multiple doses of PF-02545920 subjects with schizophrenia or schizo-affective disorder who are currently clinically stable and to evaluate the serum and urine pharmacokinetics of PF-02545920 and the N-desmethyl metabolite, PF-01001252, after multiple doses of PF-02545920 administered orally.</brief_summary>
	<brief_title>Study Investigating the Safety and Tolerability of Multiple Doses of PF-02545920 in Subjects With Schizophrenia</brief_title>
	<detailed_description />
	<mesh_term>Schizophrenia</mesh_term>
	<mesh_term>Mood Disorders</mesh_term>
	<mesh_term>Psychotic Disorders</mesh_term>
	<criteria>Subjects with DSMIV diagnosis of schizophrenia or schizoaffective disorder for whom antipsychotic monotherapy is indicated. Subjects must be free from an acute exacerbation of psychosis for at least 3 months prior to screening. Current Clinical Global Impression (CGI) of Severity of Illness score ≤3. Evidence or history of clinically significant hematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, neurological, or allergic disease (including drug allergies, but excluding untreated, asymptomatic, seasonal allergies at time of dosing). Evidence or history of a primary DSMIV axis I diagnosis other than schizophrenia or schizoaffective disorder. Any condition possibly affecting drug absorption (e.g., gastrectomy).</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>September 2007</verification_date>
</DOC>